Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Uploaded on Jan 27, 2012
Dr. Peter Martin, from Weill Cornell Medical College, explains a new class of drugs that is expanding the treatment landscape for mantle cell lymphoma, a challenging disease for which the current approaches have been ineffective or carried high risk. Called tyrosine kinase inhibitors (TKIs), these drugs have shown promising results for MCL patients in an ongoing phase II clinical trial. Dr. Martin explains the drug and the trials, and assures patients that this is just the "tip of the iceberg."